Rheias
New Helper (I got over 2000 posts)
- Reaction score
- 232
Biotechnology company Genentech Inc. said its cancer drug Avastin showed positive results in treating brain cancer over a six-month period.
The company said a midstage study of Avastin showed that 36 percent of patients given the drug lived progression-free from relapsed glioblastoma multiforme for six months. Meanwhile, 51 percent of participants given the drug in combination with chemotherapy lived progression free for six months.
Relapsed glioblastoma multiforme is the most common type of brain cancer. The results were presented at the 12th Annual Scientific Meeting of the Society for Neuro-Oncology. Avastin is already approvded to treat lung, breast and colon cancer.
The ongoing study involves 167 cancer patients who relapsed after previous treatment.
The company said a midstage study of Avastin showed that 36 percent of patients given the drug lived progression-free from relapsed glioblastoma multiforme for six months. Meanwhile, 51 percent of participants given the drug in combination with chemotherapy lived progression free for six months.
Relapsed glioblastoma multiforme is the most common type of brain cancer. The results were presented at the 12th Annual Scientific Meeting of the Society for Neuro-Oncology. Avastin is already approvded to treat lung, breast and colon cancer.
The ongoing study involves 167 cancer patients who relapsed after previous treatment.
PRESS RELEASE: Genentech, Says Avastin Shows Promise for Brain Cancer
Genentech, Says Avastin Shows Promise for Brain Cancer DALLAS -- Genentech today announced that both study arms of a randomized, multi-center Phase II clinical study of Avastin® (bevacizumab) | Genentech, Says Avastin Shows Promise for Brain Cancer DALLAS -- Genentech today announced that...
www.fiercebiotech.com
Last edited by a moderator: